Uses It has been used to treat dementia and age-related cognitive impairment (such as in Alzheimer disease), as well as to aid in recovery after stroke.  Mechanism of action Despite the fact that this drug has been used in the treatment of dementia for many years, its mechanism of action is still not clear. It stimulates dopaminergic and serotonergic receptors and blocks alpha-adrenoreceptors. Current studies imply that the major effect of hydergine may be the modulation of synaptic neurotransmission rather than solely increasing blood flow as was once thought. A prominent feature that accompanies aging is an increase in monoamine oxidase (MAO) levels. This results in decreased availability of catecholamines in the synaptic cleft. In one study, an interaction between age and hydergine treatment was observed in the hypothalamus, hippocampus and cerebellum. The hydergine effect was more pronounced in the aged group in the hypothalamus and cerebellum, and more pronounced in the adult in the hippocampus. These findings imply that increased brain MAO activity in aging can be modified by hydergine treatment in some brain regions. Trade names  Hydergine, Hydergina, Gerimal, Niloric, Redizork, Alkergot, Cicanol, Redergin, Hydrine (Thailand) Category:Antidementia agents Category: Nootropics Category:Oxazolopyrrolopyrazines Category:Lysergamides Category:Lactams Category: GABAA receptor positive allosteric modulators Category: Drugs with unknown mechanisms of actio
Medical uses It has been used to treat dementia and age-related cognitive impairment (such as in Alzheimer disease), as well as to aid in recovery after stroke. It has been used to treat hyperprolactinemia (high prolactin levels). Mechanism of action Despite the fact that this drug has been used in the treatment of dementia for many years, its mechanism of action is still not clear. It stimulates dopaminergic and serotonergic receptors and blocks alpha-adrenoreceptors. Current studies imply that the major effect of hydergine may be the modulation of synaptic neurotransmission rather than solely increasing blood flow as was once thought. A prominent feature that accompanies aging is an increase in monoamine oxidase (MAO) levels. This results in decreased availability of catecholamines in the synaptic cleft. In one study, an interaction between age and hydergine treatment was observed in the hypothalamus, hippocampus and cerebellum. The hydergine effect was more pronounced in the aged group in the hypothalamus and cerebellum, and more pronounced in the adult in the hippocampus. These findings imply that increased brain MAO activity in aging can be modified by hydergine treatment in some brain regions. Society and culture Brand names Brand names include Hydergine, Hydergina, Gerimal, Niloric, Redizork, Alkergot, Cicanol, Redergin, and Hydrine. Category:Antidementia agents Category: Drugs with unknown mechanisms of action Category: GABAA receptor positive allosteric modulators Category: Lactams Category:Lysergamides Category:Nootropics Category:Oxazolopyrrolopyrazine
R
Uses
Medical uses
A
It has been used to treat hyperprolactinemia (high prolactin levels).
R
Trade names
Society and culture
A
Brand names Brand names include
R
Hydrine (Thailand)
and Hydrine.
R
Nootropics Category:Oxazolopyrrolopyrazines Category:Lysergamides Category:Lactams Category:
Drugs with unknown mechanisms of action Category:
R
Drugs with unknown mechanisms of actio
Lactams Category:Lysergamides Category:Nootropics Category:Oxazolopyrrolopyrazine